NASDAQ · SKYE
Skye Bioscience, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SKYE: Nov 9, 2026
Skye Bioscience, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-2.56.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool · Zacks- Fintel · Sep 15, 7:17 AM EDTSkye Bioscience Average Analyst Price Target Raised 10.29% to $61.20The average one-year price target for Skye Bioscience (NASDAQCM:SKYE) has been revised to $61.20 / share. This is an increase of 10.29% from the prior estimate of $55.49 dated August 25, 2026. These figures represent aggregate analyst targets compiled from multiple sources and d
- RTTNews · Aug 21, 10:17 AM EDTWeekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks(RTTNews) – This week's global biopharma roundup captured a mix of regulatory approvals, strategic partnerships, acquisitions, and merger activity, alongside clinical trial breakthroughs and halts. Positive readouts across autoimmune myositis, glioma, and melanoma were offset by
- RTTNews · Aug 17, 4:12 AM EDTSkye To Acquire Redx; $125M Financing Secures Path To RXC008 Phase 2 Trial; Stock Up(RTTNews) – Skye Bioscience, Inc (SKYE) and Redx Pharma Ltd. announced Friday that they have entered into a definitive transaction agreement under which Skye will acquire Redx through a scheme of arrangement. Upon completion, the combined company will operate as Fibrx Therapeut
- RTTNews · Aug 14, 11:43 AM EDTSkye Bioscience, Redx Pharma To Combine To Operate As Fibrx Therapeutics(RTTNews) – Skye Bioscience, Inc. (SKYE), a biotechnology company, and privately held Redx Pharma announced a definitive transaction agreement to combine the companies and form Fibrx Therapeutics, a fibrosis-focused company expected to trade on the Nasdaq.
- RTTNews · May 21, 10:21 AM EDTSkye Receives CRC Approval For Cohort 2 In Nimacimab Expansion Study For Obesity(RTTNews) – Skye Bioscience Inc. (SKYE), a clinical-stage biotechnology company, on Wednesday reported that the Cohort Review Committee (CRC) had approved the second cohort of the CBeyond Part C expansion study for Nimacimab in treating obesity.
- RTTNews · Feb 6, 9:16 AM ESTWeekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected(RTTNews) – This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts across key therapeutic areas such as Fabry Disease, Gaucher disease, Obesity, HbA1c Reduction
- RTTNews · Feb 2, 9:35 AM ESTSkye Reports Positive Data From Extension Phase Of Phase 2a CBeyond Trial In Obesity(RTTNews) – Skye Bioscience, Inc. (SKYE), an obesity and other metabolic health disorder-focused clinical-stage biotechnology company, announced positive interim 52-week data from the combination-therapy arms in the extension Phase 2a CBeyond proof-of-concept study of nimacimab,
- RTTNews · Dec 10, 11:49 PM ESTAfter-Hours Gainers: Biotech Stocks Climb On Data Anticipation And Momentum Buying(RTTNews) – U.S. after-hours trading on Wednesday saw a wave of gains across several small-cap and micro-cap biotech names, with a mix of catalyst-driven moves and sentiment-based rebounds. While a few companies advanced on upcoming clinical milestones or recent data presentation
- The Motley Fool · Nov 18, 2:11 PM EST5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?Exited entire position: down 189,593 shares, a net position change of $5.02 million
- The Motley Fool · Nov 18, 1:55 PM EST5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands OutSold 282,313 shares for an estimated $13.33 million net change
- Zacks · Oct 7, 11:32 AM EDTSKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II GoalSkye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
- RTTNews · Oct 6, 7:50 AM EDTSkye Says CBeyond Phase 2a Study Of Nimacimab Monotherapy Did Not Meet Primary Endpoint(RTTNews) – Biotechnology company Skye Bioscience, Inc. (SKYE) announced Monday the topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Skye Bioscience, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.